, 2022 Supplementary Data from Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic ...
Peter Andrews (45652) +17 more
core +3 more sources
High-resolution positron emission microscopy of patient-derived tumor organoids. [PDF]
Nat Commun, 2021 Abstract Organoid tumor models have found application in a growing array of cancer studies due to their ability to closely recapitulate the structural and functional characteristics of solid tumors. However, organoids are too small to be compatible with common radiological tools used in oncology clinics.
Khan S +7 more
europepmc +6 more sources
Preclinical testing of oncolytic adenovirus sensitivity in patient-derived tumor organoids. [PDF]
STAR Protoc, 2021 Patient-derived organoids (PDOs) have shown the potential to reflect patient sensitivity to chemotherapeutic or targeted drugs. Recently, we showed that organoid models can also serve as a platform to screen for selectivity and potency of oncolytic adenoviruses (OAds).
Pascual-Sabater S +5 more
europepmc +4 more sources
Patient-derived Immunocompetent Tumor Organoids: A Platform for Chemotherapy Evaluation in the Context of T-cell Recognition [PDF]
, 2023 Most of anticancer compounds synthesized by chemists are primarily evaluated for their direct cytotoxic effects at the cellular level, often overlooking the critical role of the immune system.
Siyang, Liu +11 more
core +2 more sources
Frontiers in Oncology, 2023 The advent of perpetuating living organoids derived from patient tissue is a promising avenue for cancer research but is limited by difficulties with precise characterization.
Kendra D. Marr +10 more
doaj +1 more source
Patient-Derived Tumor Organoids: A Platform for Precision Therapy of Colorectal Cancer. [PDF]
Cell TransplantColorectal cancer (CRC) represents a significant cause of cancer-related mortality on a global scale. It is a highly heterogeneous cancer, and the response of patients to homogeneous drug therapy varies considerably. Patient-derived tumor organoids (PDTOs) represent an optimal preclinical model for cancer research.
Li Y, Wu W, Yao J, Wang S, Wu X, Yan J.
europepmc +4 more sources
Patient-derived tumor organoids to model drug response in gastric cancer. [PDF]
Cell Rep MedGastric cancer poses diverse treatment challenges due to its high tumor heterogeneity. Through the use of patient-derived tumor organoid (PDO) models, new research1 has identified genes and molecular signatures that are predictive of chemotherapeutic response, providing valuable insights for clinical management and translational advancements.
Vistoso Monreal A +3 more
europepmc +3 more sources
Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored Treatment. [PDF]
Cancers (Basel), 2020 Vivarelli S +4 more
europepmc +2 more sources
Application Progress of Organoids in Colorectal Cancer
Frontiers in Cell and Developmental Biology, 2022 Currently, colorectal cancer is still the third leading cause of cancer-related mortality, and the incidence is rising. It is a long time since the researchers used cancer cell lines and animals as the study subject. However, these models possess various
Lianxiang Luo +6 more
doaj +1 more source
Genetic characterization of a novel organoid from human malignant giant-cell tumor
Journal of Bone Oncology, 2023 Malignant giant-cell tumors are extremely rare bone sarcomas that transform from conventional giant-cell tumors during long periods of treatment. Owing to their rarity, no further analysis of their molecular pathogenesis exists, and thus, no standard ...
Rie Suzuki +13 more
doaj +1 more source